Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to -$1.7 billion.

  • Kyntra Bio's Retained Earnings rose 1130.57% to -$1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 billion, marking a year-over-year increase of 1130.57%. This contributed to the annual value of -$1.9 billion for FY2024, which is 258.31% down from last year.
  • As of Q3 2025, Kyntra Bio's Retained Earnings stood at -$1.7 billion, which was up 1130.57% from -$1.9 billion recorded in Q2 2025.
  • In the past 5 years, Kyntra Bio's Retained Earnings ranged from a high of -$1.0 billion in Q1 2021 and a low of -$1.9 billion during Q3 2024
  • In the last 5 years, Kyntra Bio's Retained Earnings had a median value of -$1.7 billion in 2025 and averaged -$1.6 billion.
  • In the last 5 years, Kyntra Bio's Retained Earnings plummeted by 3199.74% in 2022 and then soared by 1130.57% in 2025.
  • Kyntra Bio's Retained Earnings (Quarter) stood at -$1.3 billion in 2021, then decreased by 23.23% to -$1.6 billion in 2022, then decreased by 18.25% to -$1.8 billion in 2023, then decreased by 2.58% to -$1.9 billion in 2024, then grew by 10.46% to -$1.7 billion in 2025.
  • Its Retained Earnings stands at -$1.7 billion for Q3 2025, versus -$1.9 billion for Q2 2025 and -$1.9 billion for Q1 2025.